Published in Immunotherapy Weekly, May 2nd, 2012
"Nevertheless, approximately one-third of subjects fail to respond to these therapies and therefore significant unmet medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.